Eric David

Company: Bridge Bioscience Corp

Job title: CEO, Gene Therapy

Seminars:

Panel Discussion: Discovering the Risk: Benefit Ratio of AAV Gene Therapies & Life Limiting Indications 11:30 am

• Understanding the difference in adverse event tolerance between the different target populations • Highlighting the balance between the risk associated with AAV gene therapy and the severity and life threatening capacity of the patient's disease • Curating individual risk: benefit ratios for individual patients to understand the need for the AAV gene therapy treatmentRead more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.